Ignite Creation Date:
2024-05-06 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 2:29 PM
Study NCT ID:
NCT05319873
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2022-03-18
Brief Title:
Ribociclib Tucatinib and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-07
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-04-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-18
First Submit QC Date:
April 1 2022
Study First Post Date:
2022-04-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-17
Last Update Post Date:
2024-04-18
Last Update Post Date Type:
ACTUAL